GROINSS-V-II/GOG 270 Trial with Ate van der Zee and Brian Slomovitz - a podcast by BMJ Group

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Ate van der Zee and Brian Slomovitz to discuss the GROINSS-V-II/GOG 270 Trial. Dr. Brian Slomovitz is a Gynecologic Oncologist at Broward Health and Professor of Obstetrics and Gynecology at the Wertheim College of Medicine at Florida International University. He is an internationally recognized leader in gynecologic oncology clinical trials, specifically in immunotherapy and novel biomarker therapeutics. He also is a leader in sentinel lymph node detection for gynecologic malignancies. Dr. Ate Van der Zee is Chairman of the Board of Directors at the University Medical Center Groningen and professor of Gynaecological Oncology. His current research focuses on translational and clinical research in vulvar cancer. Together with Dr. Oonk he leads a world-wide consortium (GROINSS-V), which performs landmark clinical studies in vulvar cancer. Dr. van der Zee combines his current position chairman position with clinical work and academic research.
Highlights•Radiotherapy instead of inguinofemoral lymphadenectomy is a safe treatment option for vulvar cancer patients with a metastasis<2 mm in the sentinel node
•Radiotherapy instead of inguinofemoral lymphadenectomy is associated with less treatment-related morbidity in vulvar cancer patients with a metastasis<2 mm in the sentinel node
•Prospective phase II treatment trials with stopping rules are excellent tools to explore new diagnostic and therapeutic options and to provide evidence-based medicine in rare tumors such as vulvar cancer.•Leading a world-wide consortium (GROINSS-V) is very rewarding and great fun!

Ate van der Zee and Brian Slomovitz (@AteZee / @gyncancermd / @umcg / @browardhealth, @FIU)

Further episodes of IJGC Podcast

Further podcasts by BMJ Group

Website of BMJ Group